Overview

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in subjects with schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer